Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2484442 | 1.00 | TACR1 (0.41) | TACR1MTNR1B | |
| SCHEMBL2484439 | 1.00 | TACR1 (0.41) | TACR1MTNR1B | |
| SCHEMBL5501304 | 0.89 | TACR1 (0.41) | TACR1 | |
| SCHEMBL5414527 | 0.85 | TACR1 (0.40) | TACR1MTNR1B | |
| SCHEMBL5413960 | 0.85 | TACR1 (0.40) | TACR1MTNR1B | |
| SCHEMBL5413955 | 0.85 | TACR1 (0.40) | TACR1MTNR1B | |
| SCHEMBL5413950 | 0.85 | TACR1 (0.40) | TACR1MTNR1B | |
| SCHEMBL5413965 | 0.85 | TACR1 (0.40) | TACR1MTNR1B | |
| SCHEMBL3163726 | 0.84 | GHSR (0.41) | TACR1 | |
| SCHEMBL3163732 | 0.84 | GHSR (0.41) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117562-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| EP-2117535-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS | GLAXO GROUP LTD (GB) | 2011-10-26 | — | — | EP | disclosed |
| CN-101959513-A | Novel pharmaceutical composition | GLAXO GROUP LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | GLAXO GROUP LIMITED | 2010-12-16 | — | — | US | disclosed |
| US-20100152446-A1 | Piperidine Derivatives | NERRE THERAPEUTICS LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| EP-1921064-B1 | Pharmaceutical composition | GLAXO GROUP LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100081667-A1 | Chemical Compounds | ALVARO GIUSEPPE | 2010-04-01 | — | — | US | disclosed |
| CN-101641102-A | Pharmaceutical compositions comprising NK1 receptor antagonists and sodium channel blockers | GLAXO GROUP LTD GB | 2010-02-03 | — | — | CN | disclosed |
| CN-101641099-A | Pharmaceutical composition comprising 3, 5-diamino-6- (2, 3-dichlorophenyl) -1, 2, 4-triazine or R (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethylpyrimidine and NK1 | GLAXO GROUP LTD GB | 2010-02-03 | — | — | CN | disclosed |
| EP-1524266-A1 | Pharmaceutical composition | GLAXO GROUP LIMITED (GB) | 2005-04-20 | — | — | EP | disclosed |
| EP-1472256-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1326832-B1 | CHEMICAL COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-10-06 | — | — | EP | disclosed |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
| US-20040014770-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | US | disclosed |
| EP-1377558-A1 | [1,4]-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003066635-A1 | PIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| EP-1326832-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002081457-A1 | `1,4!-DIAZEPANE-1-CARBOXYLIC ACID DERIVATIVES PROCESS FOR THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002032867-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105688-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIAMINO-6-(2,3-DICHLOPHENYL)-1,2,4-TRIAZINE OR R(-)-2,4-DIAMINO-5-(2,3-DICHLOROPHENYL)-6-FLUOROMETHYL PYRIMIDINE AND AN NK1 | KCNJ2, SCN5A, GRIK5 | TACR1 19/4885MTNR1B 359/4885 |
| US-20040127485-A1 | 1,4! - diazepane -1- carboxylic acid derivatives process for their preparation and their use as tachykinin antagonists | NPY1R, CRHR1, GRIN1 | TACR1 24/4885MTNR1B 88/4885 |
| US-20040014770-A1 | Chemical compounds | HCK, KCNK4, GRK4 | TACR1 188/4885MTNR1B 646/4885 |
| US-20100152446-A1 | Piperidine Derivatives | NPSR1, NPY5R, NPY4R | TACR1 5/4885MTNR1B 220/4885 |
| US-20100081667-A1 | Chemical Compounds | OPRL1, OPRK1, OPRM1 | TACR1 53/4885MTNR1B 21/4885 |
| US-20100317666-A1 | Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss | HTR1A, TPH1, HTR5A | TACR1 7/4885MTNR1B 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.